AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

PRME · NASDAQ · Biotechnology

Prime Medicine

Develops Prime Editing therapies for liver, lung, and partnered cell-therapy programs.

$3.59

After-hours close−0.02 (−0.61%)

At close$3.61(−0.77%)

Something off on this page? Send us feedback.

Profile

Prime Medicine, Inc.PRMEHealth Care

Builds gene-editing therapies around the Prime Editing platform, with internal work centered on Wilson Disease, AATD, and cystic fibrosis plus partnered ex vivo T-cell programs. Revenue has come from collaboration and license agreements, while commercialization depends on clinical testing, regulatory approval, and licensed platform rights.

Develops genetic medicines using Prime Editing, a platform designed to make defined DNA edits without double-stranded DNA breaks. The active pipeline is led by liver-directed in vivo programs for Wilson Disease and AATD, with cystic fibrosis work supported by the Cystic Fibrosis Foundation and ex vivo T-cell editing partnered with Bristol Myers Squibb.

Operates from Cambridge with no approved product sales, so the business surface is pipeline execution, collaboration revenue, and access to licensed Prime Editing rights from Broad Institute, MIT, and Harvard. Research is organized through internal programs and external partners rather than commercial franchises.

Execution now centers on moving Wilson Disease into clinical study, advancing AATD regulatory work, and keeping cystic fibrosis and T-cell programs funded through collaborations. AATD remains linked to Beam arbitration, and future product revenue depends on clinical testing and regulatory approval.

Company facts

CEOAllan Reine

ListedOct 20, 2022

ExchangeNASDAQ

HeadquartersCambridge, MA

CountryUnited States

Employees146

CIK0001894562

ISINUS74168J1016

Key statistics

Market cap$652.0M

EPS (ttm)−$1.10

P/E (ttm)−3.28

ROE-188.3%

P/B16.07

P/S160.09

Dividend yield—

Beta2.28vs XLV 0.96

Year to date +2.3% · Average volume (30d) 2.7M

Analysts

Price target, next 12 months$7.50+107.8%Median of 10 analysts · vs the Aug 28 close

ConsensusBuy7 of 10 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $3.61

High$9.00+149.3%

Median$7.50+107.8%

Low$6.00+66.2%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Prior rating	Rating	Prior target	Target
Aug 25, 2026	Chardan Capital	Reiterate		Buy		$7
Aug 18, 2026	BMO Capital	Initiate		Outperform	$19	$9
Jun 29, 2026	H.C. Wainwright	Upgrade	Neutral	Buy
Jun 29, 2026	New Street	Target				$8
Jun 29, 2026	HC Wainwright & Co.	Upgrade	Neutral	Buy

Earnings

EPS

Estimate−$0.23

ReportedDue Nov 6, 2026

Revenue

Estimate$1.3M

ReportedDue Nov 6, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 6, 2026Q2 FY26	−$0.26	−$0.24	+6.7%	$2.3M	$1.2M	−48.7%	−4.22%
May 7, 2026Q1 FY26	−$0.24	−$0.28	−16.7%	$2.3M	$856.0K	−63.2%	+2.88%
Mar 3, 2026Q4 FY25	−$0.25	−$0.22	+12.0%	$1.3M	$842.0K	−34.6%	−2.60%
Nov 7, 2025Q3 FY25	−$0.28	−$0.32	−14.3%	$2.1M	$1.2M	−40.3%	−7.35%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$1.5M	$1.1M	$1.2M	$838.0K	$856.0K	$1.2M
Gross profit	$1.5M	−$749.0K	−$42.8M	$838.0K	−$1.0M	$1.2M
Operating income	−$52.4M	−$53.4M	−$54.0M	−$48.6M	−$50.7M	−$43.3M
Net income	−$51.9M	−$52.6M	−$50.6M	−$46.1M	−$49.1M	−$42.1M
Diluted EPS	−$0.40	−$0.41	−$0.32	−$0.26	−$0.28	−$0.24
Gross margin	100.0%	-67.2%	-3,491.0%	100.0%	-116.8%	100.0%
Operating margin	-3,603.3%	-4,787.2%	-4,406.0%	-5,800.5%	-5,917.5%	-3,750.9%

Fiscal years (4-quarter sums)FY21 $0 · FY22 $0 · FY23 $0 · FY24 $3.0M · FY25 $4.6M

Revenue by product · Q2 FY26

Reportable Segment$1.2M · 100%

Balance sheet, Jun 30, 2026Cash & short-term investments $95.1M · Total debt $112.5M · Total assets $249.0M · Shareholders' equity $39.8M

Dividends

No dividends on record.

Ownership

Institutions 59.80%108.00M sharesInsiders 3.59%6.48M sharesOther 36.61%66.14M shares

Shares outstanding 180.62M · Float 59.17M · 32.8% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
Liu David R. · 10 percent owner	20.24M	11.21%	Form 4	Jul 1, 2025
Robert Nelsen	18.59M	10.40%	13D	Aug 11, 2025
Alphabet Inc.	16.56M	9.17%	13F	Aug 7, 2026
Bristol-Myers Squibb Company	11.01M	8.40%	13G	Oct 4, 2024
GV 2019, L.P.	10.10M	7.50%	13G	Nov 12, 2025

Insider tradesForm 4

No open-market trades in the last 12 months.